1
|
Pastushkova LK, Rusanov VB, Goncharova AG, Nosovskiy AM, Luchitskaya ES, Kashirina DN, Kononikhin AS, Kussmaul AR, Yakhya YD, Larina IM, Nikolaev EN. Blood Plasma Proteins Associated With Heart Rate Variability in Cosmonauts Who Have Completed Long-Duration Space Missions. Front Physiol 2021; 12:760875. [PMID: 34867466 PMCID: PMC8635916 DOI: 10.3389/fphys.2021.760875] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 10/21/2021] [Indexed: 01/18/2023] Open
Abstract
The study presents the results of evaluating the changes in the concentrations of blood plasma proteins associated with heart rate variability (HRV) in cosmonauts who have completed space missions lasting about 6months. The concentrations of 125 proteins were quantified in biological samples of the cosmonauts' blood plasma. The subgroups of proteins associated with the physiological processes of the HRV autonomic regulation were identified using bioinformatic resources (Immunoglobulin heavy constant mu, Complement C1q subcomponent subunit C, Plasma serine protease inhibitor, Protein-72kDa type IV collagenase, Fibulin-1, Immunoglobulin lambda constant 3). The concentration of these proteins in the blood plasma before the flight, and the dynamics of concentration changes on the 1st and 7th days of the post-flight rehabilitation period differed in the groups of cosmonauts with a predominance of sympathetic or parasympathetic modulating autonomous influences. The dynamics of changes in the concentrations of the identified set of proteins reveal that in cosmonauts with a predominance of sympathetic modulating influences, the mechanisms of autonomic regulation are exposed to significant stress in the recovery period immediately after the completion of the space mission, compared with the cosmonauts with a predominance of parasympathetic modulating influences.
Collapse
Affiliation(s)
| | - Vasily B. Rusanov
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | - Anna G. Goncharova
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | - Andrei M. Nosovskiy
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | - Elena S. Luchitskaya
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | - Daria N. Kashirina
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | - Alexey S. Kononikhin
- Skolkovo Institute of Science and Technology, Skolkovo, Russia
- V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Center of Chemical Physics, Russian Academy of Sciences, Moscow, Russia
| | - Anna R. Kussmaul
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | - Yusef D. Yakhya
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | - Irina M. Larina
- Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia
| | | |
Collapse
|
2
|
Lobo YA, Bonazza C, Batista FP, Castro RA, Bonturi CR, Salu BR, de Cassia Sinigaglia R, Toma L, Vicente CM, Pidde G, Tambourgi DV, Alvarez-Flores MP, Chudzinski-Tavassi AM, Oliva MLV. EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines. Cancer Lett 2020; 491:108-120. [PMID: 32841713 DOI: 10.1016/j.canlet.2020.08.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 07/21/2020] [Accepted: 08/14/2020] [Indexed: 01/08/2023]
Abstract
Breast cancer is the most common malignant tumor among women worldwide, and triple-negative breast cancer is the most aggressive type of breast cancer, which does not respond to hormonal therapies. The protease inhibitor, EcTI, extracted from seeds of Enterolobium contortisiliquum, acts on the main signaling pathways of the MDA-MB-231 triple-negative breast cancer cells. This inhibitor, when bound to collagen I of the extracellular matrix, triggers a series of pathways capable of decreasing the viability, adhesion, migration, and invasion of these cells. This inhibitor can interfere in the cell cycle process through the main signaling pathways such as the adhesion, Integrin/FAK/SRC, Akt, ERK, and the cell death pathway BAX and BCL-2. It also acts by reducing the main inflammatory cytokines such as TGF-α, IL-6, IL-8, and MCP-1, besides NFκB, a transcription factor, responsible for the aggressive and metastatic characteristics of this type of tumor. Thus, the inhibitor was able to reduce the main processes of carcinogenesis of this type of cancer.
Collapse
Affiliation(s)
- Yara A Lobo
- Biochemistry, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Camila Bonazza
- Gynecology, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Fabrício P Batista
- Biochemistry, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Rodrigo A Castro
- Gynecology, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Camila R Bonturi
- Biochemistry, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Bruno R Salu
- Biochemistry, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Rita de Cassia Sinigaglia
- Electron Microscopy Center at the Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Leny Toma
- Biochemistry, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Carolina M Vicente
- Biochemistry, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil
| | - Giselle Pidde
- Immunochemistry, Instituto Butantan, Av. Vital Brasil, 1500, São Paulo, 05503-900, SP, Brazil
| | - Denise V Tambourgi
- Immunochemistry, Instituto Butantan, Av. Vital Brasil, 1500, São Paulo, 05503-900, SP, Brazil
| | - Miryam P Alvarez-Flores
- Center of Excellence in New Target Discovery (CENTD), Instituto Butantan, Av. Vital Brasil, 1500, São Paulo, 05503-900, SP, Brazil
| | - Ana M Chudzinski-Tavassi
- Center of Excellence in New Target Discovery (CENTD), Instituto Butantan, Av. Vital Brasil, 1500, São Paulo, 05503-900, SP, Brazil
| | - Maria Luiza V Oliva
- Biochemistry, Universidade Federal de São Paulo, 04044-020, São Paulo, SP, Brazil.
| |
Collapse
|